Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Other Accumulated Expenses (2016 - 2025)

Viking Therapeutics' Other Accumulated Expenses history spans 12 years, with the latest figure at $23.3 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 36.05% year-over-year to $23.3 million; the TTM value through Dec 2025 reached $23.3 million, up 36.05%, while the annual FY2025 figure was $23.3 million, 36.05% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $23.3 million at Viking Therapeutics, up from $21.2 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $27.2 million in Q1 2024 and bottomed at $7.3 million in Q4 2021.
  • The 5-year median for Other Accumulated Expenses is $11.3 million (2023), against an average of $13.7 million.
  • The largest annual shift saw Other Accumulated Expenses soared 238.32% in 2024 before it tumbled 58.22% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $7.3 million in 2021, then soared by 79.52% to $13.1 million in 2022, then dropped by 13.84% to $11.3 million in 2023, then surged by 51.44% to $17.1 million in 2024, then surged by 36.05% to $23.3 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Other Accumulated Expenses are $23.3 million (Q4 2025), $21.2 million (Q3 2025), and $26.0 million (Q2 2025).